Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1007/s00262-019-02446-1.pdf
Reference36 articles.
1. Carbognin L, Pilotto S, Milella M et al (2015) Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PloS One 10:e0130142. https://doi.org/10.1371/journal.pone.0130142
2. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011
3. Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004–2012. https://doi.org/10.1200/JCO.2014.58.3708
4. Rizvi NA, Garon EB, Patnaik A et al (2014) Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 32:8007. https://doi.org/10.1200/jco.2014.32.15_suppl.8007
5. Rizvi NA, Shepherd FA, Antonia SJ et al (2014) First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status: metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 90:S31. https://doi.org/10.1016/j.ijrobp.2014.08.204
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Assessment of thoracic tumors by FAPI PETCT: a systematic evaluation and meta-analysis;2023-11-21
2. Virtual screening to investigate the potential targets and mechanisms of action of "Astragalus-Ligustrum" drug pair in the treatment of non-small cell lung cancer;2023-09-20
3. A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer;Cancers;2023-07-28
4. Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes;Frontiers in Oncology;2023-06-07
5. A unique gene signature predicting recurrence-free survival in stage IA lung adenocarcinoma;The Journal of Thoracic and Cardiovascular Surgery;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3